C-Path, CDISC Develop Standard to Represent Data for Animal Rule Studies TUCSON, Ariz. and AUSTIN, Texas, October 15, 2019 — The Critical Path Institute (C-Path) and CDISC are pleased to announc
Innovative Data and Analytics Platform to Accelerate Drug Development for Rare Diseases Launched by C-Path and NORD through an FDA grant, the goal of the new platform is to accelerate the development of cures by addres
C-Path’s Martha A. Brumfield Named Arizona Bioscience Leader of the Year CHANDLER, Ariz., Sept. 18, 2019 — The Arizona Bioindustry Association (AZBio) today announced that Martha A. Brumf
Funded by FDA, C-Path and NORD to Launch Rare Disease Data and Analytics Platform The collaborative project between the organizations will kick off at a launch meeting in September and will aim to r
C-Path Taps Medical Science Operations Executive Kristen Swingle as Chief Operating Officer TUCSON, Ariz., July 2, 2019 — The Critical Path Institute (C-Path) is pleased to announce that after an extensive
C-Path’s PSTC Releases Points to Consider Outlining Recommendations for Analytical Validation of Assays Used in Qualifying Biomarkers The document serves as a guide to the analysis of biomarkers in drug development TUCSON, Ariz., June 11, 2019 — The Critical Pat
C-Path, CDISC Release Therapeutic Area Standard to Drive Research Forward for Clostridium Difficile Associated Diarrhea TUCSON, Ariz. and AUSTIN, May 2, 2019 — The Critical Path Institute (C-Path) and CDISC are pleased to announce the relea
C-Path, CDISC Develop Therapeutic Area Standard to Foster More Efficient and Meaningful Research for HIV TUCSON, Ariz. and AUSTIN, April 16, 2019 — The Critical Path Institute (C-Path) and CDISC are pleased to announce
C-Path Receives Qualification for the Asthma Daytime Symptom Diary (ADSD) and the Asthma Nighttime Symptom Diary (ANSD) TUCSON, Ariz., April 9, 2019 — Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium announces U.S.
Critical Path Institute and Japan’s Pharmaceuticals and Medical Devices Agency Collaborate on First-of-its-Kind Biomarker Project Aim is to generate critical data to support safety decisions made in early-stage clinical trials TUCSON, Ariz., March 26, 2
